Quick Answer
Silence Therapeutics plc reported Stockholders Equity of $62.30 million for fiscal year 2025.
Silence Therapeutics plc Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $62.30M | -53.5% |
| 2024 | $134.02M | +509.4% |
| 2023 | $21.99M | -19.2% |
| 2022 | $27.22M | +120.0% |
| 2021 | $12.37M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $74.06M | -41.5% | -21.3% |
| June 30, 2025 | $94.16M | -33.9% | -16.5% |
| March 31, 2025 | $112.74M | -28.1% | -15.9% |
| December 31, 2024 | $134.02M | +509.4% | +5.8% |
| September 30, 2024 | $126.70M | — | -11.1% |
| June 30, 2024 | $142.53M | — | -9.1% |
| March 31, 2024 | $156.76M | — | +612.8% |
| December 31, 2023 | $21.99M | — | — |
- Silence Therapeutics plc showed a decrease of -53.5% in Stockholders Equity compared to the prior fiscal year.
- Over the 2021–2025 period, Silence Therapeutics plc’s stockholders equity has grown by 403.5% (from $12.37 million to $62.30 million).
- The most recent figure is from Silence Therapeutics plc’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: